Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Regeneron和賽諾菲安萬特將發佈第3期LIBERTY-CUPID研究C研究數據,評估Dupixent;稱Dupixent將瘙癢和蕁麻疹活動從基線降低,41%的患者實現了疾病狀態得到良好控制
Regeneron And Sanofi To Present Phase 3 LIBERTY-CUPID Study C Study Data Evaluating Dupixent; Says Dupixent Reduced Itch And Hive Activity From Baseline, 41% Of Patients Achieved Well-Controlled Disease Status
Regeneron和賽諾菲安萬特將發佈第3期LIBERTY-CUPID研究C研究數據,評估Dupixent;稱Dupixent將瘙癢和蕁麻疹活動從基線降低,41%的患者實現了疾病狀態得到良好控制
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。